A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Trastuzumab emtansine [Kadcyla] 3.0 mg/kg|DRUG: Trastuzumab emtansine [Kadcyla] 3.6 mg/kg|DRUG: Pertuzumab 420 mg
Sponsor: Hoffmann-La Roche
Collaborators: Roche Pharma AG